Table 4.
Disparities in breast cancer risk and survival among African American and Non-Hispanic White women.
| Characteristic | African American | Non-hispanic white | p-value |
|---|---|---|---|
| Incidence rate (2014)a | 122.4/100,000 | 124.8/100,000 | |
| Mortality rate (2014)a | 28.1/100,000 | 20.0/100,000 | |
| Five-year survival 2005–2011(%)b | 80 | 91 | |
| High tumor grade (%)c | 64.6 | 43 | |
| Breast cancer subtyped | |||
| Hormone receptor positive (%) | 42.9 | 67.3 | <0.001 |
| HER2 positive (%) | 16.8 | 17.1 | 0.96 |
| Triple negative (%) | 36.3 | 13.7 | <0.001 |
| Gene mutationse | |||
| TP53 mutation (%) | 46.3 | 27.3 | <0.001 |
| MLL3 (%) | 11.6 | 6.1 | 0.033 |
| PIK3CA (%) | 23.1 | 33.8 | 0.021 |
| Proliferation markerf | |||
| Ki67 >10% | 88 | 54 | <0.001 |
| Inflammatory cytokinesg | |||
| IL-6 (pg/ml) | 4.51 | 0.88 | |
| Resistin (ng/ml) | 18.8 | 7.33 | |
MLL3, Histone-lysine N-methyltransferase.
PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase.
IL-6, Interleukin-6.
Ki67, Marker of proliferation.
Data from:
a
US Cancer Statistics: 1999–2014 Incidence and Mortality. Web-based report available at http://www.cdc.gov/uscs.
b
ACS. Cancer Facts & Figures for African Americans. 2016–2018. Atlanta: ACS, 2016.
c
Warner et al. (81).
d
Keenan et al. (82).
e
Ademuyiwa et al. (83).
f
Sullivan et al. (84).
g
Deshmukh et al. (85).